Thomas L. Tran, Former Chief Financial Officer of Molina Healthcare, Joins Clover Health’s Board of Directors
Rhea-AI Summary
Clover Health (NASDAQ: CLOV) has appointed Thomas L. Tran to its Board of Directors and Audit Committee. Tran, with over 35 years of financial leadership in healthcare, most recently served as CFO of Upstream Care and previously as CFO of Molina Healthcare. CEO Andrew Toy highlighted Tran's expertise in strategic financial planning for public managed care organizations as a significant asset for Clover's mission of empowering physicians and improving health outcomes through technology. Tran expressed enthusiasm for Clover's innovative approach to Medicare and value-based care, stating his commitment to helping shape the company's vision.
Positive
- Appointment of Thomas L. Tran, an experienced healthcare finance leader, to the Board of Directors
- Enhancement of strategic financial planning capabilities with Tran's expertise in public managed care organizations
- Strengthening of the Audit Committee with Tran's addition
Negative
- None.
News Market Reaction – CLOV
In the trading session that priced this news, CLOV declined 4.00%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FRANKLIN, Tenn., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced it has appointed Thomas L. Tran to the Company’s Board of Directors (the "Board"), and as a member of the Audit Committee.
“Tom Tran’s appointment to our Board marks a significant enhancement to our strategic financial planning and execution capabilities. With his impressive track record at the helm of finance at public managed care organizations, Tom is uniquely qualified to help guide Clover Health as we advance our mission of empowering physicians and improving health outcomes through innovative technology,” said Andrew Toy, Chief Executive Officer of Clover Health.
Mr. Tran has over 35 years of financial leadership experience in the healthcare industry and has previously held leadership roles at various prominent managed care companies. Most recently, from February 2022 to June 2023, Mr. Tran served as chief financial officer and as a director of Upstream Care, a value-based physician enablement innovator focused on the Medicare population. From June 2018 to May 2021, he served as chief financial officer of Molina Healthcare, Inc. Mr. Tran earned his Bachelor’s degree from Seton Hall University and his Master of Business Administration degree from New York University.
“Having dedicated my career to improving healthcare through better financial and operational strategies, I find Clover Health's mission very compelling. I believe Clover’s innovative use of technology to drive better health outcomes represents the future of Medicare. I am excited to join the Board and help shape this vision, ensuring Clover continues to lead in value-based care,” said Mr. Tran.
About Clover Health:
Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a health equity-based focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we aim to extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology’s impact on Medication Adherence, as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.
Press Contact:
Andrew Still-Baxter
press@cloverhealth.com
Investor Relations Contact:
Ryan Schmidt
investors@cloverhealth.com
